InvestorsHub Logo
Followers 84
Posts 12467
Boards Moderated 0
Alias Born 07/25/2008

Re: None

Friday, 05/17/2019 8:40:34 AM

Friday, May 17, 2019 8:40:34 AM

Post# of 425963
Very Bearish for AMRN:

• Matinas BioPharma (NYSEMKT:MTNB) is up 4% premarket on increased volume on the heels of a Buy rating and $5 (434% upside) price target at BTIG Research citing the potential of next-gen omega-3 fatty acid compound MAT9001 that Matinas says is superior to Amarin's (NASDAQ:AMRN) Vascepa (icosapent ethyl) in lowering high triglycerides.

I’m lighting up, but not today..
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News